Comparative Pharmacology
Head-to-head clinical analysis: BRIUMVI versus FASENRA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BRIUMVI versus FASENRA.
BRIUMVI vs FASENRA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
BRIUMVI (ublituximab) is a recombinant, chimeric, humanized monoclonal antibody that binds to CD20, a transmembrane antigen expressed on pre-B and mature B lymphocytes. Binding to CD20 results in antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC), leading to B-cell depletion.
Benralizumab is a humanized afucosylated monoclonal antibody that binds to the alpha subunit of the interleukin-5 receptor (IL-5Rα) expressed on eosinophils and basophils. This binding inhibits IL-5-mediated signaling and induces antibody-dependent cell-mediated cytotoxicity (ADCC), resulting in rapid and near-complete depletion of eosinophils from blood and tissues.
BRIUMVI (ublituximab) 150 mg administered as an intravenous infusion over 4 hours once weekly for 3 weeks, then 150 mg once every 6 months thereafter.
30 mg subcutaneously every 4 weeks for the first 3 doses, then every 8 weeks thereafter.
None Documented
None Documented
Terminal elimination half-life is approximately 19-20 days (range 11-30 days) in patients with relapsing multiple sclerosis. The long half-life supports every-6-month dosing.
Terminal half-life approximately 25 days (range 24–27 days), supporting every-4-week subcutaneous dosing.
BRIUMVI (ublituximab) is a monoclonal antibody. Elimination occurs via intracellular catabolism and is not excreted renally or fecally in significant amounts. No specific excretion data available.
Degraded into small peptides and amino acids via general protein catabolism; no significant renal or biliary/fecal excretion of intact drug.
Category C
Category C
Monoclonal Antibody
Monoclonal Antibody, Anti-Interleukin-5 Receptor